This database serves as the latest addition to the market intelligence products already under DeciBio Consulting's umbrella.
Such products include the Emmes Infectious Disease Database, the Emmes Oncology Database, BioMAP (immuno-oncology biomarkers), Marketbooks, Dexter, and BioTrack, among others.
The DeciBio Emmes SARS-CoV-2 Testing Database provides data visualization tools and raw data covering coronavirus testing practices in approximately 400 labs in the United States.
This data includes diagnostic and serology testing details at hospital, public health, and commercial reference labs, as well as send-out volumes.
Example preliminary results indicate that, although the supply of kits and the adoption of in-house testing continue to increase:
Nearly half of labs have reported that kit availability fails to meet demand; consequently, one third of surveyed labs use multiple platforms. Testing at these labs account for a majority of total volumes for the database.
Some labs have reported reduced operational hours affecting testing outputs.
Serology test adoption is beginning to mature but lags behind diagnostic testing.
The SARS-CoV-2 Testing Database collects information on platforms and kits used, sample collection devices, co-testing behaviors, and more.
Startups, test manufacturers, and Fortune 500 Life Science companies alike are using this database to keep a finger on the pulse of the rapidly evolving SARS-CoV-2 testing environment and adapt accordingly.
The database and easy-to-navigate visualization suite are available on a subscription basis for clients in sales, development, strategic, investment analytics / market research, and operations roles.
DeciBio Consulting is a strategy consulting firm focused on precision medicine. DeciBio offers advisory services for growth planning, market and opportunity assessment, product and portfolio strategy, and corporate due diligence.
The Emmes databases are managed and marketed through DeciBio Consulting's market intelligence subsidiary, DeciBio Analytics. Through the Emmes databases and other products, DeciBio Analytics aggregates public and proprietary data to build proprietary software and data visualization products.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial